Catalyst Pharmaceuticals (CPRX) Operating Income: 2009-2024
Historic Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $195.1 million.
- Catalyst Pharmaceuticals' Operating Income rose 30.17% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 48.74%. This contributed to the annual value of $195.1 million for FY2024, which is 124.77% up from last year.
- Per Catalyst Pharmaceuticals' latest filing, its Operating Income stood at $195.1 million for FY2024, which was up 124.77% from $86.8 million recorded in FY2023.
- Catalyst Pharmaceuticals' Operating Income's 5-year high stood at $195.1 million during FY2024, with a 5-year trough of $41.3 million in FY2020.
- Its 3-year average for Operating Income is $127.9 million, with a median of $101.8 million in 2022.
- Per our database at Business Quant, Catalyst Pharmaceuticals' Operating Income decreased by 14.75% in 2023 and then spiked by 124.77% in 2024.
- Over the past 5 years, Catalyst Pharmaceuticals' Operating Income (Yearly) stood at $41.3 million in 2020, then grew by 26.83% to $52.4 million in 2021, then soared by 94.40% to $101.8 million in 2022, then fell by 14.75% to $86.8 million in 2023, then skyrocketed by 124.77% to $195.1 million in 2024.